Volanesorsen, an antisense oligonucleotide targeting APOCIII mRNA, has recently emerged as a promising treatment for refractory or severe hypertriglyceridemia, including patients with familial chylomicronemia syndrome. This evidence concerns the gene APOC3 and hypertriglyceridemia.